Table 2. Risk factors/etiologies of CLD, and ultrasound findings of the liver in relation to their association with hospital outcome.
| Characteristics | n, (%) | Survivor(n = 78) | Non-survivors (n = 31) | p-value |
|---|---|---|---|---|
| Risk factors/Etiology of CLD a | ||||
| HBsAg + | 39(35.8%) | 30(75%) | 10(25%) | 0.544 |
| Alcoholic | 15(13.8%) | 10(66.7%) | 5(33.3%) | 0.651 |
| Anti-HCV+ | 12(11.0%) | 9(69.2%) | 4(30.8%) | 0.843 |
| Hepatic schistosomiasis | 7(6.4%) | 5(6.4%) | 2(6.5%) | 0.994 |
| Unidentified | 28(25.7%) | 17(21.8%) | 11(35.5%) | 0.140 |
| Ultrasound findings | ||||
| Advanced liver fibrosis | ||||
| Nodular liver surface | 19(17.4%) | 13(16.7%) | 6(19.4%) | 0.739 |
| Coarse echotexture | 16(14.7%) | 12(15.4%) | 4(12.9%) | 0.741 |
| Splenomegaly | 37(33.9%) | 29(37.2%) | 8(25.8%) | 0.258 |
| Liver fibrosis/inflammation | ||||
| Increased echogenicity | 21(19.3%) | 13(16.7%) | 8(25.8%) | 0.275 |
| Heterogeneous echotexture | 19(17.4%) | 9(11.5%) | 10(32.3%) | 0.010ǂ |
| Mild uneven liver surface | 3(2.8%) | 2(2.6%) | 1(3.2%) | 1.000 |
| Periportal fibrosis | 7(6.4%) | 5(6.4%) | 2(6.5%) | 0.994 |
| Hepatocellular carcinoma | 19(17.4%) | 11(14.1%) | 8(25.8%) | 0.146 |
| Ascites | 101(92.7%) | 71(91%) | 30(96.8%) | 0.299 |
| Others | 10(9.2%) | 9(11.5%) | 1(3.2%) | 0.175 |
a HBsAg + and anti-HCV+, Autoimmune hepatitis, Wilson`s disease, biliary cirrhosis, Fatty liver
ǂ Statistically significant